PROVIDE研究:初始万古霉素暴露与MRSA血流感染治疗失败的前瞻性观察评估
该前瞻性多中心观察研究纳入265例住院成人MRSA血流感染患者,评估万古霉素第2天AUC/MIC与治疗失败的关系。结果发现达到预设AUC/MIC阈值并未降低治疗失败风险,但较高暴露与急性肾损伤相关;第2天AUC≤515者全局结局最佳。
要点
- 达到第2天AUC/MIC阈值(肉汤微量稀释≥650或Etest≥320)未降低治疗失败风险。
- 第2天AUC与急性肾损伤相关,AUC≤515者无治疗失败且无AKI。
- 万古霉素剂量应根据AUC指导,第2天AUC宜≤515。
核心结论
- 较高的万古霉素暴露未降低治疗失败风险,反而与更多急性肾损伤相关。
- 第2天AUC≤515的患者全局结局最佳(无治疗失败且无AKI)。
- 万古霉素剂量应依据AUC指导,第2天AUC应≤515。
研究设计与样本
- 前瞻性、多中心(n=14)观察性研究,纳入265例接受万古霉素治疗的住院成人MRSA血流感染患者。
主要发现
- 治疗失败(30天死亡或持续菌血症≥7天)发生率为18%,急性肾损伤发生率为26%。
- 达到预设的第2天AUC/MIC阈值(肉汤微量稀释≥650或Etest≥320)与较低的治疗失败风险无关。
- 未发现与较低治疗失败风险相关的其他第2天AUC/MIC阈值。
- 观察到第2天AUC与急性肾损伤之间存在关联。
- 第2天AUC≤515的患者全局结局最佳(无治疗失败且无AKI)。
关键数值与推荐
- 预设共同主要终点阈值:第2天AUC/MIC(肉汤微量稀释法)≥650和AUC/MIC(Etest法)≥320。
- 第2天AUC≤515与最佳全局结局相关。
- 第2天AUC<400的患者很少,需进一步研究确定治疗范围下限。
临床怎么用
- 万古霉素 dosing 应依据AUC指导,而非仅追求高AUC/MIC阈值。
- 第2天AUC目标宜控制在≤515以平衡疗效与肾毒性风险。
局限性
- 第2天AUC<400的患者数量少,治疗范围下限尚未明确。
- 需进一步研究定义万古霉素治疗窗的下限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is the most commonly administered antibiotic in hospitalized patients, but optimal exposure targets remain controversial. To clarify the therapeutic exposure range, this study evaluated the association between vancomycin exposure and outcomes in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. METHODS: This was a prospective, multicenter (n = 14), observational study of 265 hospitalized adults with MRSA bacteremia treated with vancomycin. The primary outcome was treatment failure (TF), defined as 30-day mortality or persistent bacteremia ≥7 days. Secondary outcomes included acute kidney injury (AKI). The study was powered to compare TF between patients who achieved or did not achieve day 2 area under the curve to minimum inhibitory concentration (AUC/MIC) thresholds previously found to be associated with lower incidences of TF. The thresholds, analyzed separately as co-primary endpoints, were AUC/MIC by broth microdilution ≥650 and AUC/MIC by Etest ≥320. RESULTS: Treatment failure and AKI occurred in 18% and 26% of patients, respectively. Achievement of the prespecified day 2 AUC/MIC thresholds was not associated with less TF. Alternative day 2 AUC/MIC thresholds associated with lower TF risks were not identified. A relationship between the day 2 AUC and AKI was observed. Patients with day 2 AUC ≤515 experienced the best global outcomes (no TF and no AKI). CONCLUSIONS: Higher vancomycin exposures did not confer a lower TF risk but were associated with more AKI. The findings suggest that vancomycin dosing should be guided by the AUC and day 2 AUCs should be ≤515. As few patients had day 2 AUCs <400, further study is needed to define the lower bound of the therapeutic range.
引用
- Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis. 2020. PMID: 31157370. doi:10.1093/cid/ciz460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。